Ranibizumab for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO)
Medical Services Advisory Committee
Record ID 32015000423
English
Authors' objectives:
This service is for use of optical coherence tomography in the diagnosis and monitoring of treatment with ranibizumab in patients with retinal vein occlusion.
RVO is the second most sight-threatening retinal vascular disease after diabetic retinopathy. If untreated, RVO does not resolve in the majority of patients but results in visual impairment and significant ocular complications. RVO is not a chronic condition; it is an acute event that causes reduced retinal perfusion, retinal ischaemia and increased production of vascular endothelial growth factor (VEGF). Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A) and is considered a treatment option.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1350-public
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Tomography, Optical Coherence
- Macular Edema
- Retinal Vein Occlusion
- Antibodies, Monoclonal, Humanized
- Angiogenesis Inhibitors
- Ranibizumab
- Visual Acuity
- Intravitreal Injections
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
Copyright:
<p>Medical Services Advisory Committee (MSAC)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.